Gene expression panel for immuno-oncology research, 11/14

November 2014—NanoString Technologies announced a highly multiplexed gene expression panel for the nCounter Analysis System, the PanCancer Immune Profiling Panel. The panel will enable researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies, and predictive biomarker signatures for immunotherapy treatment response.

The panel is designed to provide researchers with a tool to facilitate advancements in research, including targeting of checkpoint blockades, development of chimeric antigen receptors for T-cell therapy, and identification of adjuvants for stimulating the immune response in the tumor microenvironment.

The panel comprises 770 genes, including more than 100 genes for the identification of 24 different immune cell types, 30 genes specific for the expression of recognized cancer antigens, genes involved with checkpoint blockade, and immune pathway genes for innate adaptive and humoral immune responses.

NanoString Technologies, 888-358-6266